NCI-H2110 Cells

NCI-H2110 is a human non-small cell lung cancer (NSCLC) cell line derived from a lung adenocarcinoma. Established as part of the NCI-Navy Medical Oncology Branch panel, this cell line is widely used for studying the biology of NSCLC and evaluating the efficacy of targeted and cytotoxic therapies. It grows as an adherent epithelial monolayer under standard in vitro conditions, typically cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum.

Molecular profiling of NCI-H2110 has revealed an activating KRAS mutation, a key oncogenic driver that promotes constitutive activation of the MAPK/ERK and PI3K/AKT signaling pathways. This places the cell line among a subset of NSCLC models resistant to EGFR inhibitors but potentially sensitive to therapies targeting downstream effectors of KRAS signaling. Its mutation profile and pathway dependencies have made NCI-H2110 a valuable tool in pharmacogenomic analyses, including those exploring drug sensitivities across large cell line panels such as the Cancer Cell Line Encyclopedia (CCLE).

In addition to its use in drug screening platforms, NCI-H2110 has been featured in transcriptomic and epigenomic studies that investigate chromatin accessibility, histone modifications, and gene expression patterns. Its well-characterized genetic background supports mechanistic studies of resistance to kinase inhibitors and helps elucidate the broader molecular landscape of KRAS-mutant lung adenocarcinomas.